{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:26:36Z","timestamp":1793424396455,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T19:30:54Z","timestamp":1752953454000},"page":"57-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Arvin K.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranko","family":"Miocinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir R.","family":"Rastinehad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian D.","family":"Stensland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Helfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Gahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne G.","family":"Brisbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Vourganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Baha","family":"Barqawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Uchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Polascik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.06.003_b0005","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER cancer stat facts: prostate cancer. Bethesda, MD: National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.eururo.2025.06.003_b0010","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2025.06.003_b0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5694\/mja2.50820","article-title":"Understanding the diagnosis of prostate cancer","volume":"213","author":"Ong","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.eururo.2025.06.003_b0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00345-020-03525-0","article-title":"Making a case \u201cfor\u201d focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials","volume":"39","author":"Wang","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.003_b0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.06.003_b0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.003_b0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-biophys-052118-115451","article-title":"Membrane electroporation and electropermeabilization: mechanisms and models","volume":"48","author":"Kotnik","year":"2019","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.eururo.2025.06.003_b0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2020192190","article-title":"High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy","volume":"295","author":"Geboers","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.06.003_b0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/153303460700600106","article-title":"Irreversible electroporation: a new ablation modality \u2014 clinical implications","volume":"6","author":"Rubinsky","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.eururo.2025.06.003_b0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bju.14951","article-title":"Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment","volume":"125","author":"Blazevski","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.06.003_b0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0075","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00345-016-1782-x","article-title":"Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project","volume":"34","author":"Postema","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0080","unstructured":"United States Food and Drug Administration. De novo classification request for Sonablate\u00ae 450. 2015."},{"key":"10.1016\/j.eururo.2025.06.003_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.06.003_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.003_b0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/bju.13983","article-title":"Focal irreversible electroporation as primary treatment for localized prostate cancer","volume":"121","author":"van den Bos","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.06.003_b0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bju.15946","article-title":"Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer","volume":"131","author":"Scheltema","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.06.003_b0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41391-023-00783-y","article-title":"A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer","volume":"27","author":"Zhang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.06.003_b0110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.juro.2016.09.091","article-title":"Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer","volume":"197","author":"Valerio","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/pcan.2014.33","article-title":"Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer","volume":"17","author":"Valerio","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.06.003_b0120","article-title":"Quality of life and safety outcomes following irreversible electroporation treatment for prostate cancer: results from a phase I-II study","volume":"7","author":"Van den Bos","year":"2015","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/j.eururo.2025.06.003_b0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2016.02.2986","article-title":"Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer","volume":"196","author":"Murray","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JU.0000000000001327","article-title":"Impact of focal versus whole gland ablation for prostate cancer on sexual function and urinary continence","volume":"205","author":"Borges","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.06.003_b0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jvir.2015.10.020","article-title":"Thermal energy during irreversible electroporation and the influence of different ablation parameters","volume":"27","author":"van den Bos","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.eururo.2025.06.003_b0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5152\/dir.2018.17374","article-title":"Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments","volume":"24","author":"Scheltema","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.eururo.2025.06.003_b0145","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/cancers16122178","article-title":"A description and safety overview of irreversible electroporation for prostate tissue ablation in intermediate-risk prostate cancer patients: preliminary results from the PRESERVE trial","volume":"16","author":"George","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500346X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500346X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:41:42Z","timestamp":1765986102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382500346X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S030228382500346X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}